secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001437749-26-014547
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q1 net loss $18.6M; accelerates NANOPULSE-AF enrollment to early Q4 2026
--------------------------------------------------------------------------------

- Preliminary Q1 2026: cash $68.3M, net loss $18.6M, cash used in ops $14.6M.
- Product revenue $0.4M; R&D $12.6M, SG&A $6.6M; costs up $1.6M YoY.
- NANOPULSE-AF U.S. IDE pivotal trial enrollment now expected to complete early Q4 2026.
- NANOCLAMP-AF surgical trial enrollment target: end of H1 2027.
- Added Dr. David Kenigsberg as full-time CMO and Liane Teplitsky as COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926014547/0001437749-26-014547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926014547/plse20260312_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-014547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer